Back to top
more

Ayr Wellness Inc. (AYRWF)

(Delayed Data from OTC)

$0.01 USD

0.01
1,102,031

0.00 (120.00%)

Updated Aug 6, 2025 12:49 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Stryker (SYK) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of +2.29% and +1.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -33.33% and 0.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 0% and 9.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of -14.29% and 5.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verano Holdings Corp. (VRNOF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 40% and 2.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo (MYO) delivered earnings and revenue surprises of 0% and 6.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -41.38% and 0.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

InfuSystems Holdings (INFU) delivered earnings and revenue surprises of -50% and 1.61%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LeMaitre Vascular (LMAT) Meets Q4 Earnings Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of 0% and 0.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -62.96% and 5.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rockwell Medical (RMTI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 400% and 8.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Baxter International (BAX) Beats Q3 Earnings Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 2.56% and 29.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Warby Parker Inc. (WRBY) Q3 Earnings Match Estimates

by Zacks Equity Research

Warby Parker (WRBY) delivered earnings and revenue surprises of 0% and 1.58%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevia (ZVIA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zevia (ZVIA) delivered earnings and revenue surprises of 63.64% and 5.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -30.77% and 1.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Owens & Minor (OMI) Stock Jumps 7.6%: Will It Continue to Soar?

by Zacks Equity Research

Owens & Minor (OMI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

Are Medical Stocks Lagging Avinger (AVGR) This Year?

by Zacks Equity Research

Here is how Avinger (AVGR) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -58.82% and 2.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 2.27% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OraSure Technologies (OSUR) Q1 Earnings Meet Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of 0% and 3.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is Ayr Wellness Inc. (AYRWF) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Ayr Wellness Inc. (AYRWF) and Align Technology (ALGN) have performed compared to their sector so far this year.

Zacks Equity Research

Why Fast-paced Mover Ayr Wellness Inc. (AYRWF) Is a Great Choice for Value Investors

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.